My concern with the COVID-19 ARDS trial is that it is taking so long to do the enrollments. With the number of deaths in US I thought we'd see full enrollment in the first couple months. The total US death count as of October 7th for "Deaths involving COVID-19 and Pneumonia, excluding influenza" (the most likely group for ARDS and ventilator therapy in my view) is 89,981. https://www.cdc.gov/nchs/nvss/vsrr/covid19/index.htm
I remember distinctly reading something back around the time Mesoblast initiated it's COVID-19 ARDS trial that some US agency was going to coordinate the allocation of patients into the many COVID-19 trials in order to supposedly improve the overall outcomes. I wonder if there is some slow-walking going on regarding allocation of patients to the Mesoblast trial. Worse yet would be a deliberate allocation of patients with worst prognosis to trials. I guess I'm just not a trusting person these days...
DYOR and TFY (Think for Yourself)
Competition - Citius Novellus License Deal, page-5
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.040(2.65%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.48 | $1.45 | $2.567M | 1.757M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1400 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 20509 | 7 |
View Market Depth
| Last trade - 11.10am 08/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |